{"organizations": [], "uuid": "6b4a9915f3a7aa9116261030a5eedcbae55edb28", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180305.html", "section_title": "Archive News &amp; Video for Monday, 05 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-santhera-pharmaceuticals-reports-o/brief-santhera-pharmaceuticals-reports-outcome-of-exploratory-trial-with-idebenone-in-ppms-conducted-at-nih-idUSFWN1QN02T", "country": "US", "domain_rank": 408, "title": "BRIEF-Santhera Pharmaceuticals ‍Reports Outcome Of Exploratory Trial With Idebenone In PPMS Conducted At NIH​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.923, "site_type": "news", "published": "2018-03-05T14:30:00.000+02:00", "replies_count": 0, "uuid": "6b4a9915f3a7aa9116261030a5eedcbae55edb28"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-santhera-pharmaceuticals-reports-o/brief-santhera-pharmaceuticals-reports-outcome-of-exploratory-trial-with-idebenone-in-ppms-conducted-at-nih-idUSFWN1QN02T", "ord_in_thread": 0, "title": "BRIEF-Santhera Pharmaceuticals ‍Reports Outcome Of Exploratory Trial With Idebenone In PPMS Conducted At NIH​", "locations": [], "entities": {"persons": [{"name": "santhera", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "nih", "sentiment": "negative"}, {"name": "exploratory", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 5 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING Ag :\n* ‍REPORTS OUTCOME OF EXPLORATORY TRIAL WITH IDEBENONE IN PPMS CONDUCTED AT NIH​\n* SANTHERA - ‍EXPLORATORY PHASE I/II CLINICAL TRIAL CONFIRMS SAFETY PROFILE OF IDEBENONE AT A DOSE OF 2,250 MG DAILY OVER A TREATMENT PERIOD OF TWO YEARS​\n* SANTHERA - ‍IN ASSESSING EFFICACY ON DISEASE PROGRESSION, NO DIFFERENCE BETWEEN ACTIVE TREATMENT GROUP AND PLACEBO WAS OBSERVED​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-05T14:30:00.000+02:00", "crawled": "2018-03-06T22:28:56.000+02:00", "highlightTitle": ""}